Skip to main content
. 2021 Feb 16;10(2):406. doi: 10.3390/cells10020406

Table 3.

Clinical features with respect to checkpoint inhibitor therapy for PFS. PFS values were summarized in terms of median and interquartile range (1st and 3rd quartiles).

Features PFS (Months)
M Stage
 M1a 8 (3–30)
 M1b 3 (3–36.5)
 M1c 3 (2–3)
 M1d 2 (2–3)
ECOG
 0 9 (3–32)
 1 3 (2–5)
 2 2 (2–3)
LDH
 <ULN 3 (3–27)
 ≥ULN 3 (2–3)
Number of Metastatic Sites
 < 3 3 (3–24)
 ≥3 3 (2–3)